Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib after Trastuzumab in Early-Stage HER2+ Breast Cancer
NCT00878709Phase 3Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Jul 2009
- Primary completion
- Aug 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 40
01
Overview
A Phase 3 trial of neratinib in breast cancer, sponsored by Puma Biotechnology, Inc.. Started Jul 2009; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00878709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00878709.